Regeneron Pharmaceuticals, Inc.
Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors

Abstract:

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.